Efficacy and Safety of Stem Cell Therapy for Spinal Cord Injury in Adults: A Systematic Review and Meta-Analysis

Authors

  • Anadya Rhadika RS Pusat Otak Nasional, Jakarta, Indonesia
  • Sultan Adhitya Romano Universitas YARSI, Jakarta, Indonesia
  • Himawan Widyatmiko Emergency Department, RSUD Pandega Pangandaran, West Java, Indonesia
  • Andrew Wilbert Tanuwijaya Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia
  • Putu Surya Pradipta Hariantha Putra Universitas Udayana, Bali, Indonesia
  • Salma Rizqi Amanah Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia
  • Abdelrahman Ramadan Elashry College of Medicine, University of Sharjah, Sharjah, UAE
  • Sarmad Javaid Sharif Medical and Dental College, Lahore, Pakistan
  • Made Agus Mahendra Inggas Department of Neurosurgery, Universitas Pelita Harapan, Tangerang, Banten, Indonesia
  • Jeremiah Hilkiah Wijaya School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

DOI:

https://doi.org/10.19166/med.v15i1.10762

Keywords:

Spinal cord injury, stem cell therapy, neuroregeneration, mesenchymal stem cells, AIS improvement

Abstract

Background: Despite encouraging early results, clinical outcomes remain inconsistent across trials. This study aimed to systematically evaluate the efficacy and safety of stem cell therapy in adults with spinal cord injury (SCI).

 

Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. PubMed, EMBASE, and Scopus were searched until 18 October 2025. Eligible studies included adult SCI patients receiving stem cell therapy with measurable neurological outcomes. Data synthesis was performed using Review Manager 5.4 under a random-effects model, reporting pooled risk ratios (RR) with 95% confidence intervals (CIs). Risk of bias was assessed using ROBINS-I, and evidence certainty was graded via GRADE.

 

Result: Thirteen studies involving 470 participants (286 intervention, 184 control) were included. Stem cell therapy significantly improved neurological recovery compared with controls (RR = 2.64; 95% CI 1.70–4.10; p < 0.0001; I² = 0%). Subgroup analyses showed consistent benefits across baseline AIS classifications (RR = 2.61; 95% CI 1.71–3.98) and cell doses (RR = 2.75; 95% CI 1.63–4.64). No major safety signals were identified. GRADE assessment rated the certainty of efficacy evidence as moderate.

 

Conclusions: Stem cell therapy yields significant neurological improvement in adult SCI with a favorable safety profile. The findings support its regenerative potential through neuroprotective and remyelinating mechanisms. However, larger randomized controlled trials are required to validate efficacy, optimize protocols, and assess long-term safety.

References

1. Zeng CW. Advancing Spinal Cord Injury Treatment through Stem Cell Therapy: A Comprehensive Review of Cell Types, Challenges, and Emerging Technologies in Regenerative Medicine. Int J Mol Sci. 2023 Sept 20;24(18):14349. https://doi.org/10.3390/ijms241814349

2. Kawai M, Nagoshi N, Okano H, Nakamura M. A review of regenerative therapy for spinal cord injury using human iPS cells. North American Spine Society Journal (NASSJ). 2023 Mar;13:100184. https://doi.org/10.1016/j.xnsj.2022.100184

3. Kataria S, Patel U, Yabut K, Patel J, Patel R, Patel S, et al. Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options. Curr Pain Headache Rep. 2024 May;28(5):321–33. https://doi.org/10.1007/s11916-024-01227-5

4. Xiao J, Yang R, Biswas S, Qin X, Zhang M, Deng W. Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis. IJMS. 2015 Apr 24;16(5):9283–302. https://doi.org/10.3390/ijms16059283

5. Protain HJ, Kutzler MA, Valentine BA. Assessment of cytologic evaluation of preputial epithelial cells as a diagnostic test for detection of adrenocortical disease in castrated ferrets. Am J Vet Res. 2009 May;70(5):619–23. https://doi.org/10.2460/ajvr.70.5.619

6. Thanaskody K, Jusop AS, Tye GJ, Wan Kamarul Zaman WS, Dass SA, Nordin F. MSCs vs. iPSCs: Potential in therapeutic applications. Front Cell Dev Biol. 2022;10:1005926. https://doi.org/10.3389/fcell.2022.1005926

7. Zun-wei X, Gui-xiang C, Yi-zhao L. Curative effect of autologous mesenchymal stem cell transplantation on spinal cord injury. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2007;11(7):1277-1279.

8. Huang L, Fu C, Xiong F, He C, Wei Q. Stem Cell Therapy for Spinal Cord Injury. Cell Transplant. 2021;30:963689721989266. https://doi.org/10.1177/0963689721989266

9. Anwar MA, Al Shehabi TS, Eid AH. Inflammogenesis of Secondary Spinal Cord Injury. Front Cell Neurosci. 2016;10:98. https://doi.org/10.3389/fncel.2016.00098

10. Darehbagh RR, Seyedoshohadaei SA, Ramezani R, Rezaei N. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024 July 25;29(1):386. https://doi.org/10.1186/s40001-024-01987-1

11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372(n71):1-9. https://doi.org/10.1136/bmj.n71

12. Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146–56. https://doi.org/10.1016/j.jcyt.2020.08.008

13. Cheng H, Liu X, Hua R, Dai G, Wang X, Gao J, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. J Transl Med. 2014 Sept 12;12:253. https://doi.org/10.1186/s12967-014-0253-7

14. Chernykh ER, Stupak VV, Muradov GM, Sizikov MY, Shevela EY, Leplina OY, et al. Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients. Bull Exp Biol Med. 2007 Apr;143(4):543–7. https://doi.org/10.1007/s10517-007-0175-y

15. Chhabra HS, Sarda K, Arora M, Sharawat R, Singh V, Nanda A, et al. Autologous bone marrow cell transplantation in acute spinal cord injury--an Indian pilot study. Spinal Cord. 2016 Jan;54(1):57–64. https://doi.org/10.1038/sc.2015.134

16. Dai G, Liu X, Zhang Z, Yang Z, Dai Y, Xu R. Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res. 2013 Oct 2;1533:73–9. https://doi.org/10.1016/j.brainres.2013.08.016

17. El-Kheir WA, Gabr H, Awad MR, Ghannam O, Barakat Y, Farghali HAMA, et al. Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transplant. 2014 Apr;23(6):729–45. https://doi.org/10.3727/096368913x664540

18. Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, et al. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clinical Neurology and Neurosurgery. 2021 Apr;203:106565. https://doi.org/10.1016/j.clineuro.2021.106565

19. Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg. 2012 Sept;114(7):935–9. https://doi.org/10.1016/j.clineuro.2012.02.003

20. Shin JC, Kim KN, Yoo J, Kim IS, Yun S, Lee H, et al. Clinical Trial of Human Fetal Brain-Derived Neural Stem/Progenitor Cell Transplantation in Patients with Traumatic Cervical Spinal Cord Injury. Neural Plast. 2015;2015:630932. https://doi.org/10.1155/2015/630932

21. Yang Y, Pang M, Du C, Liu ZY, Chen ZH, Wang NX, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy. 2021 Jan;23(1):57–64. https://doi.org/10.1016/j.jcyt.2020.09.012

22. Yoon SH, Shim YS, Park YH, Chung JK, Nam JH, Kim MO, et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells. 2007 Aug;25(8):2066–73. https://doi.org/10.1634/stemcells.2006-0807

23. Nguyen H, Zarriello S, Coats A, Nelson C, Kingsbury C, Gorsky A, et al. Stem cell therapy for neurological disorders: A focus on aging. Neurobiol Dis. 2019 June;126:85–104. https://doi.org/10.1016/j.nbd.2018.09.011

24. Tang X, Deng P, Li L, He Y, Wang J, Hao D, et al. Advances in genetically modified neural stem cell therapy for central nervous system injury and neurological diseases. Stem Cell Res Ther. 2024 Dec 18;15(1):482. https://doi.org/10.1186/s13287-024-04089-1

25. Zanier ER, Pischiutta F, Rulli E, Vargiolu A, Elli F, Gritti P, et al. MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a study protocol for a multicenter, double-blind, randomised, placebo-controlled phase II trial. Intensive Care Med Exp. 2023 Aug 25;11(1):56. https://doi.org/10.1186/s40635-023-00535-1

26. Shen Z, Tang X, Zhang Y, Jia Y, Guo X, Guo X, et al. Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis. Stem Cells Transl Med. 2024 Sept 10;13(9):886–97. https://doi.org/10.1093/stcltm/szae040

27. Chopra M, Kumar H. Navigating the complexities of spinal cord injury: an overview of pathology, treatment strategies and clinical trials. Drug Discovery Today. 2025 June;30(6):104387. https://doi.org/10.1016/j.drudis.2025.104387

28. Kaminska A, Radoszkiewicz K, Rybkowska P, Wedzinska A, Sarnowska A. Interaction of Neural Stem Cells (NSCs) and Mesenchymal Stem Cells (MSCs) as a Promising Approach in Brain Study and Nerve Regeneration. Cells. 2022 Apr 26;11(9):1464. https://doi.org/10.3390/cells11091464

29. Hsu YC, Lee DC, Chiu IM. Neural Stem Cells, Neural Progenitors, and Neurotrophic Factors. Cell Transplant. 2007 Feb;16(2):133–50. Available from: https://pubmed.ncbi.nlm.nih.gov/17474295/

30. De Gioia R, Biella F, Citterio G, Rizzo F, Abati E, Nizzardo M, et al. Neural Stem Cell Transplantation for Neurodegenerative Diseases. IJMS. 2020 Apr 28;21(9):3103. https://doi.org/10.3390/ijms21093103

Downloads

Published

2025-10-01

How to Cite

Rhadika, A., Romano, S. A., Widyatmiko, H., Tanuwijaya, A. W., Putra, P. S. P. H., Amanah, S. R., … Wijaya, J. H. (2025). Efficacy and Safety of Stem Cell Therapy for Spinal Cord Injury in Adults: A Systematic Review and Meta-Analysis. Medicinus, 15(1), 66–80. https://doi.org/10.19166/med.v15i1.10762

Issue

Vol. 15 No. 1 (2025): October

Section

Clinical Article

License

Copyright (c) 2025 Anadya Rhadika, Sultan Adhitya Romano, Himawan Widyatmiko, Andrew Wilbert Tanuwijaya, Putu Surya Pradipta Hariantha Putra, Salma Rizqi Amanah, Abdelrahman Ramadan Elashry, Sarmad Javaid, Made Agus Mahendra Inggas, Jeremiah Hilkiah Wijaya

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.